Small-cell lung carcinoma staging

Koukourakis MI, B ahlitzanakis N, Froudarakis M, et al. Concurrentconventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIB non-small cell lung carcinoma. BrJ Cancer 1999 80 1792-1796. 

Levitan N, Dowlati A, Shina D, et al. Multi-institutional phase ITU trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol 2000 18(5) 1102-1109. 

Gy in favorable patients with radiation oncology group stage III non small cell lung carcinoma Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990 8 1543-1555. 

Strauss GM, Langer MP, Elias AD, et al. Multimodality treatment of stage IIIA non-small cell lung carcinoma A critical review of the literature and strategies for future research. J Clin Oncol 1992 10 829-838. 

Choi N, Carey R. Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small-cell lung carcinoma an update. Int J Radiat Oncol Biol Phys 1989 17 307-310. 

Janne PA, Friedlin B, Saxman S, Johnson DH, Livingston RB, Shepherd FA et al. Twenty-five years of chnical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002 95 1528-38. 

Vohra P, Cagle PT, Allen TC, et al. Tissue microarray study of RNA-binding protein IMP3 in primary non-small cell lung cancers Prediction of survival in early stage squamous cell carcinomas. Mod Pathol. 2008 21 352A. 

Non small cell lung cancer (NSCLC) remains the leading cause of cancer deaths in both men and women in the Western World. NSCLC accounts for approximately 75% of all lung carcinomas and 35% of patients with NSCLC will present with stage lllA or lllB disease. The majority of these patients with mediastinal involvement are not amenable to surgical resection, and primary radiation therapy alone results in 5-year actuarial survival of only 3%-7% and a median survival time of 6-11 months (Jeremic et al. 1996). Combined modality therapy is now considered the standard of care for those patients with unresectable tumors and a good performance status. 

While the natural history of this malignancy involves early seeding of distant metastases, those patients who have localized or limited-stage small-cell carcinoma of the lung have potentially curable tumors where combined chemoradiation is important. 

Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage Ilia non-small cell carcinoma of the lung report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992 10 1237-1244. 

Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung A meta-analysis. J Clin Oncol 1992 10(6) 890-895. 

Ludwig Lung Cancer Study Group. Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1985 89(6) 842-7. 

---